On this page
Silver Sulfadiazine
Overview
Active ingredients
Source: NDC DirectoryForms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Sulfonamide Antibacterial [EPC] | EPC | 6 members — no class page |
| Sulfonamides [CS] | CS | All 18 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 018810-001 | THERMAZENE | CREAM | SILVER SULFADIAZINE | Prescription | AB |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 20 | Manufacturing (CMC) | Approved | August 11, 2016 | N/A |
| Supplement | 19 | Manufacturing (CMC) | Approved | November 27, 2012 | Standard |
| Supplement | 12 | Manufacturing (CMC) | Approved | September 27, 2001 | Standard |
| Supplement | 11 | Manufacturing (CMC) | Approved | August 7, 1997 | Standard |
| Supplement | 8 | Labeling | Approved | May 10, 1990 | — |
| Supplement | 7 | Manufacturing (CMC) | Approved | October 24, 1989 | Standard |
| Supplement | 6 | Manufacturing (CMC) | Approved | May 30, 1989 | Standard |
| Supplement | 5 | Manufacturing (CMC) | Approved | April 12, 1989 | Standard |
| Supplement | 4 | Manufacturing (CMC) | Approved | January 12, 1987 | Standard |
| Supplement | 2 | Manufacturing (CMC) | Approved | November 17, 1986 | Standard |
| Supplement | 1 | Manufacturing (CMC) | Approved | November 17, 1986 | Standard |
| Supplement | 3 | Manufacturing (CMC) | Approved | November 4, 1986 | Standard |
| Original application | 1 | Type 5 - New Formulation or New Manufacturer | Approved | December 23, 1985 | Standard |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260713). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Silver sulfadiazine cream, USP 1% is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION: FOR TOPICAL USE ONLY - NOT FOR OPHTHALMIC USE: Prompt institution of appropriate regimens for care of the burned patient is of prime importance and includes the control of shock and pain. The burn wounds are then cleansed and debrided; Silver Sulfadiazine Cream is then applied under sterile conditions. The burn areas should be covered with Silver Sulfadiazine Cream at all times. The cream should be applied once to twice daily to a thickness of approximately one sixteenth of an inch. Whenever necessary, the cream should be reapplied to any areas from which it has been removed due to patient activity. Administration may be accomplished in minimal time because dressings are not required. However, if individual patient requirements make dressings necessary, they may be used. Reapply immediately after hydrotherapy. Treatment with Silver Sulfadiazine Cream should be continued until satisfactory healing has occurred or until the burn site is ready for grafting. The drug should not be withdrawn from the therapeutic regimen while there remains the possibility of infection except if a significant adverse reaction occurs.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Silver sulfadiazine cream, USP 1% is contraindicated in patients who are hypersensitive to silver sulfadiazine or any of the other ingredients in the preparation. Because sulfonamide therapy is known to increase the possibility of kernicterus, silver sulfadiazine cream, USP 1% should not be used on pregnant women approaching or at term, on premature infants, or on newborn infants during the first 2 months of life.
Warnings and Cautions
openFDA Drug LabelingWarnings and Precautions Absorption of silver sulfadiazine varies depending upon the percent of body surface area and the extent of the tissue damage. Although few have been reported, it is possible that any adverse reaction associated with sulfonamides may occur. Some of the reactions which have been associated with sulfonamides are as follows: blood dyscrasias including agranulocytosis, aplastic anemia, thrombocytopenia, leukopenia, and hemolytic anemia; dermatologic and allergic reactions, including life-threatening cutaneous reactions [Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and exfoliative dermatitis]; gastrointestinal reactions, hepatitis and hepatocellular necrosis; CNS reactions; and toxic nephrosis. There is a potential cross-sensitivity between silver sulfadiazine and other sulfonamides. If allergic reactions attributable to treatment with silver sulfadiazine occur, continuation of therapy must be weighed against the potential hazards of the particular allergic reaction. Fungal proliferation in and below the eschar may occur. However, the incidence of clinically reported fungal superinfection is low. The use of silver sulfadiazine cream, USP 1% in some cases of glucose-6-phosphate dehydrogenase-deficient individuals may be hazardous, as hemolysis may occur. General. If hepatic and renal functions become impaired and elimination of the drug decreases accumulation may occur. Discontinuation of silver sulfadiazine cream, USP 1% should be weighed against the therapeutic benefit being achieved. In considering the use of topical proteolytic enzymes in conjunction with Silver sulfadiazine cream, USP 1% the possibility should be noted that silver may inactivate such enzymes. Laboratory Tests. In the treatment of burn wounds involving extensive areas of the body, the serum sulfa concentrations may approach adult therapeutic levels (8 to 12mg %). Therefore, in these patients it would be advisable to monitor serum sulfa concentrations. Renal function should be carefully monitored and the urine should be checked for sulfa crystals. Absorption of the propylene glycol vehicle has been reported to affect serum osmolality, which may affect the interpretation of laboratory tests. Carcinogenesis, Mutagenesis, Impairment of Fertility. Long-term dermal toxicity studies of 24 months duration in rats and 18 months in mice with concentrations of silver sulfadiazine three to ten times the concentration in silver sulfadiazine cream, USP 1% revealed no evidence of carcinogenicity.
Warnings
openFDA Drug LabelingWARNINGS Absorption of silver sulfadiazine varies depending upon the percent of body surface area and the extent of the tissue damage. Although few have been reported, it is possible that any adverse reaction associated with sulfonamides may occur. Some of the reactions which have been associated with sulfonamides are as follows: blood dyscrasias including agranulocytosis, aplastic anemia, thrombocytopenia, leukopenia, and hemolytic anemia; dermatologic and allergic reactions, including life-threatening cutaneous reactions [Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and exfoliative dermatitis]; gastrointestinal reactions, hepatitis and hepatocellular necrosis; CNS reactions; and toxic nephrosis. There is a potential cross-sensitivity between silver sulfadiazine and other sulfonamides. If allergic reactions attributable to treatment with silver sulfadiazine occur, continuation of therapy must be weighed against the potential hazards of the particular allergic reaction. Fungal proliferation in and below the eschar may occur. However, the incidence of clinically reported fungal superinfection is low. The use of silver sulfadiazine cream, USP 1% in some cases of glucose-6-phosphate dehydrogenase-deficient individuals may be hazardous, as hemolysis may occur.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS SECTION Several cases of transient leucopenia have been reported in patients receiving silver sulfadiazine therapy. Leucopenia associated with silver sulfadiazine administration is primarily characterized by decreased neutrophil count. Maximal white blood cell depression occurs within two to four days of initiation of therapy. Rebound to normal leukocyte levels follows onset within two to three days. Recovery is not influenced by continuation of silver sulfadiazine therapy. The incidence of leucopenia in various reports averages about 20%. A higher incidence has been seen in patients treated concurrently with cimetidine. Other infrequently occurring events include skin necrosis, erythema multiforme, skin discoloration, burning sensation, rashes, and interstitial nephritis. Reduction in bacterial growth after application of topical antibacterial agents has been reported to permit spontaneous healing of deep partial thickness burns by preventing conversion of the partial thickness to full thickness by sepsis. However, reduction in bacterial colonization has caused delayed separation, in some cases necessitating escharotomy in order to prevent contracture. Absorption of silver sulfadiazine varies depending upon the percent of body surface area and the extent of the tissue damage. Although few have been reported, it is possible that any adverse reaction associated with sulfonamides may occur. Some of the reactions which have been associated with sulfonamides are as follows: blood dyscrasias, agranulocytosis, aplastic anemia, thrombocytopenia, leucopenia, hemolytic anemia, dermatologic reactions, allergic reactions, Stevens-Johnson syndrome, exfoliative dermatitis, gastrointestinal reactions, hepatitis, hepatocellular necrosis, CNS reactions, and toxic nephrosis.
Description
openFDA Drug LabelingDESCRPITION SSDTM (1% Silver Sulfadiazine Cream) and SSD AFTM (1% Silver Sulfadiazine Cream), 1% are topical antibacterial preparations which have as their active antimicrobial ingredient silver sulfadiazine. The active moiety is contained within an opaque, white, water miscible cream base. Each 1000 grams of SSD/SSD AF Cream contains 10 grams of silver sulfadiazine. Inactive Ingrediants: cetyl alcohol (SSD Cream only), isopropyl myristate, polyoxyl 40 stearate, propylene glycol, purified water, stearyl alcohol, sodium hydroxide, sorbitan monooleate, white petrolatum; with 0.3% methyl paraben, as a preservative. Silver sulfadiazine has an emprical formula of C 10 H 9 AgN 4 O 2 S, molecular weight of 357.14 and structural formula as shown: Structure for silver sulfadiazine
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Silver sulfadiazine cream, USP 1% - white to off-white cream NDC Number Size 87063-078-20 (relabeled from NDC 67877-124-20) 20g tube 87063-078-25 (relabeled from NDC 67877-124-25) 25g tube 87063-078-05 (relabeled from NDC 67877-124-05) 50g tube 87063-078-85 (relabeled from NDC 67877-124-85) 85g tube 87063-078-50 (relabeled from NDC 67877-124-50) 50g jar 87063-078-40 (relabeled from NDC 67877-124-40) 400g jar 87063-078-10 (relabeled from NDC 67877-124-10) 1000g jar Store at room temperature. 15°-30°C (59°-86°F). Relabeled by: Enovachem PHARMACEUTICALS Torrance, CA 90501
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: SILVER SULFADIAZINE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 50090-0607-0 | 50090-0607 | A-S Medication Solutions | 50 g in 1 JAR (50090-0607-0) | November 28, 2014 |
| 50090-0717-0 | 50090-0717 | A-S Medication Solutions | 50 g in 1 TUBE (50090-0717-0) | November 28, 2014 |
| 50090-0763-0 | 50090-0763 | A-S Medication Solutions | 25 g in 1 TUBE (50090-0763-0) | November 28, 2014 |
| 50090-2152-0 | 50090-2152 | A-S Medication Solutions | 400 g in 1 JAR (50090-2152-0) | October 21, 2015 |
| 80425-0221-1 | 80425-0221 | Advanced Rx Pharmacy of Tennessee, LLC | 50 g in 1 TUBE (80425-0221-1) | January 12, 2023 |
| 67877-124-05 | 67877-124 | Ascend Laboratories, LLC | 50 g in 1 TUBE (67877-124-05) | December 23, 1985 |
| 67877-124-10 | 67877-124 | Ascend Laboratories, LLC | 1000 g in 1 JAR (67877-124-10) | December 23, 1985 |
| 67877-124-20 | 67877-124 | Ascend Laboratories, LLC | 20 g in 1 TUBE (67877-124-20) | December 23, 1985 |
| 67877-124-25 | 67877-124 | Ascend Laboratories, LLC | 25 g in 1 TUBE (67877-124-25) | December 23, 1985 |
| 67877-124-40 | 67877-124 | Ascend Laboratories, LLC | 400 g in 1 JAR (67877-124-40) | December 23, 1985 |
| 67877-124-50 | 67877-124 | Ascend Laboratories, LLC | 50 g in 1 JAR (67877-124-50) | December 23, 1985 |
| 67877-124-85 | 67877-124 | Ascend Laboratories, LLC | 85 g in 1 TUBE (67877-124-85) | December 23, 1985 |
| 76420-208-25 | 76420-208 | Asclemed USA, Inc. | 25 g in 1 TUBE (76420-208-25) | March 9, 2022 |
| 76420-208-50 | 76420-208 | Asclemed USA, Inc. | 50 g in 1 TUBE (76420-208-50) | March 9, 2022 |
| 87063-078-05 | 87063-078 | Asclemed USA, Inc. | 50 g in 1 TUBE (87063-078-05) | January 23, 2026 |
| 87063-078-10 | 87063-078 | Asclemed USA, Inc. | 1000 g in 1 JAR (87063-078-10) | January 23, 2026 |
| 87063-078-20 | 87063-078 | Asclemed USA, Inc. | 20 g in 1 TUBE (87063-078-20) | January 23, 2026 |
| 87063-078-25 | 87063-078 | Asclemed USA, Inc. | 25 g in 1 TUBE (87063-078-25) | January 23, 2026 |
| 87063-078-40 | 87063-078 | Asclemed USA, Inc. | 400 g in 1 JAR (87063-078-40) | January 23, 2026 |
| 87063-078-50 | 87063-078 | Asclemed USA, Inc. | 50 g in 1 JAR (87063-078-50) | January 23, 2026 |
| 87063-078-85 | 87063-078 | Asclemed USA, Inc. | 85 g in 1 TUBE (87063-078-85) | January 23, 2026 |
| 61919-237-25 | 61919-237 | DIRECT RX | 25 g in 1 TUBE (61919-237-25) | January 1, 2015 |
| 59762-0131-0 | 59762-0131 | Mylan Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (59762-0131-0) / 20 g in 1 TUBE | February 9, 2018 |
| 59762-0131-2 | 59762-0131 | Mylan Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (59762-0131-2) / 25 g in 1 TUBE | February 9, 2018 |
| 59762-0131-4 | 59762-0131 | Mylan Pharmaceuticals Inc. | 400 g in 1 JAR (59762-0131-4) | January 16, 2018 |
| 59762-0131-5 | 59762-0131 | Mylan Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (59762-0131-5) / 50 g in 1 TUBE | January 16, 2018 |
| 59762-0131-6 | 59762-0131 | Mylan Pharmaceuticals Inc. | 50 g in 1 JAR (59762-0131-6) | January 16, 2018 |
| 59762-0131-8 | 59762-0131 | Mylan Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (59762-0131-8) / 85 g in 1 TUBE | January 16, 2018 |
| 68071-2473-5 | 68071-2473 | NuCare Pharmaceuticals,Inc. | 50 g in 1 TUBE (68071-2473-5) | July 8, 2021 |
| 63187-023-25 | 63187-023 | Proficient Rx LP | 25 g in 1 TUBE (63187-023-25) | November 1, 2018 |
| 63187-023-51 | 63187-023 | Proficient Rx LP | 50 g in 1 TUBE (63187-023-51) | February 14, 2024 |
| 50090-0607 | 50090-0607 | A-S Medication Solutions | — | December 23, 1985 |
| 50090-0717 | 50090-0717 | A-S Medication Solutions | — | December 23, 1985 |
| 50090-0763 | 50090-0763 | A-S Medication Solutions | — | December 23, 1985 |
| 50090-2152 | 50090-2152 | A-S Medication Solutions | — | December 23, 1985 |
| 80425-0221 | 80425-0221 | Advanced Rx Pharmacy of Tennessee, LLC | — | January 12, 2023 |
| 67877-124 | 67877-124 | Ascend Laboratories, LLC | — | December 23, 1985 |
| 76420-208 | 76420-208 | Asclemed USA, Inc. | — | May 4, 2011 |
| 87063-078 | 87063-078 | Asclemed USA, Inc. | — | December 23, 1985 |
| 61919-237 | 61919-237 | DIRECT RX | — | January 1, 2014 |
| 59762-0131 | 59762-0131 | Mylan Pharmaceuticals Inc. | — | January 15, 2018 |
| 68071-2473 | 68071-2473 | NuCare Pharmaceuticals,Inc. | — | May 4, 2011 |
| 63187-023 | 63187-023 | Proficient Rx LP | — | December 23, 1985 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 11 sections on this page.